These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 32776357)

  • 1. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
    Savarese G; Hage C; Benson L; Schrage B; Thorvaldsen T; Lundberg A; Fudim M; Linde C; Dahlström U; Rosano GMC; Lund LH
    J Intern Med; 2021 Mar; 289(3):369-384. PubMed ID: 32776357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
    Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C
    ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
    Desai AS; Vaduganathan M; Cleland JG; Claggett BL; Barkoudah E; Finn P; McCausland FR; Yilmaz MB; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Dec; 14(12):e008597. PubMed ID: 34807713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
    Dewan P; Shen L; Pedro Ferreira J; Jhund PS; Anand IS; Chandra A; Chiang LM; Claggett B; Desai AS; Gong J; Lam CSP; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Solomon SD; McMurray JJV
    Circulation; 2024 Jul; 150(4):272-282. PubMed ID: 38841854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
    Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
    Suzuki K; Claggett B; Minamisawa M; Nochioka K; Mitchell GF; Anand IS; Zannad F; Shah SJ; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
    Hypertension; 2021 Feb; 77(2):546-556. PubMed ID: 33356401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
    Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
    Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
    J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
    Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
    J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.
    Norberg H; Bergdahl E; Lindmark K
    ESC Heart Fail; 2018 Apr; 5(2):337-343. PubMed ID: 29345425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
    Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E;
    J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.